Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial - 01/09/16
, Tanya B Dorff, MD b, Paul Elson, ScD a, Cristina Suarez Rodriguez, MD c, Dale Shepard, MD a, Laura Wood, MSN a, Jordi Humbert, BSc c, Linda Pyle, RN d, Yu-Ning Wong, MD e, James H Finke, ProfPhD a, Patricia A Rayman, MS a, James M G Larkin, FRCP d, Jorge A Garcia, MD a, Elizabeth R Plimack, MD eSummary |
Background |
A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit from initial active surveillance. We aimed to characterise the time to initiation of systemic therapy in patients with metastatic renal-cell carcinoma under active surveillance.
Methods |
In this prospective phase 2 trial, we enrolled patients with treatment-naive, asymptomatic, metastatic renal-cell carcinoma from five hospitals in the USA, Spain, and the UK. Patients were radiographically assessed at baseline, every 3 months for year 1, every 4 months for year 2, then every 6 months thereafter. Patients continued on observation until initiation of systemic therapy for metastatic renal-cell carcinoma; a decision that was made at the discretion of the treating physician and patient. The primary endpoint of the study was time to initiation of systemic therapy in the per-protocol population. The follow-up of patients is ongoing.
Findings |
Between Aug 21, 2008, and June 7, 2013, we enrolled 52 patients. Median follow-up of patients in the study was 38·1 months (IQR 29·4–48·9). In the 48 patients included in analysis, median time on surveillance from registration on study until initiation of systemic therapy was 14·9 months (95% CI 10·6–25·0). Multivariate analysis showed that higher numbers of International Metastatic Database Consortium (IMDC) adverse risk factors (p=0·0403) and higher numbers of metastatic disease sites (p=0·0414) were associated with a shorter surveillance period. 22 (46%) patients died during the study period, all from metastatic renal-cell carcinoma.
Interpretation |
A subset of patients with metastatic renal-cell carcinoma can safely undergo surveillance before starting systemic therapy. Additional investigation is required to further define the benefits and risks of this approach.
Funding |
None.
Le texte complet de cet article est disponible en PDF.Plan
Vol 17 - N° 9
P. 1317-1324 - septembre 2016 Retour au numéro
Article précédent
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- Fred Saad, Joan Carles, Silke Gillessen, Axel Heidenreich, Daniel Heinrich, Jeremy Gratt, Jérémy Lévy, Kurt Miller, Sten Nilsson, Oana Petrenciuc, Marcello Tucci, Manfred Wirth, Judith Federhofer, Joe M O’Sullivan, Radium-223 International Early Access Program Investigators †
- Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude Lifetime Cohort Study
- Nickhill Bhakta, Qi Liu, Frederick Yeo, Malek Baassiri, Matthew J Ehrhardt, Deo K Srivastava, Monika L Metzger, Matthew J Krasin, Kirsten K Ness, Melissa M Hudson, Yutaka Yasui, Leslie L Robison
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?